Safety Evaluation of Adverse Reactions in Diabetes

Inclusion Criteria: * Type 2 diabetes mellitus * Metformin monotherapy - stable dose during last 3 months * HbA1C 48-75 mmol/mol (IFCC) * BMI 25-40 kg/m2 * Age 35-70 years (women postmenopausal) * Use of ACE inhibitors or ATII receptor blockers for at least 3 months before enrollment Exclusion Criteria: * eGFR\<30 ml/min/1.73m2 (MDRD) * Treatment with incretin mimetics during 3 months before enrollment * Chronic insulin therapy * Chronic use of loop diuretics, glucocorticoids, NSAID, immune suppressants, antimicrobial agents, chemotherapeutics, bile acid sequestrants (colestyramin, colesevelam) * History of pancreatic disease or impaired pancreatic function (defined as the need to use pancreatic enzymes) * Active liver disease or a 3-fold elevation of liver transaminases (ALT, AST) * Active malignancy * History of severe cardiovascular disease including acute coronary syndrome, stroke or transient ischemic neurologic disorder during previous 6 months, atrial fibrillation or other arrhythmia requiring chronic antiarrhythmic medication, chronic heart failure (New York Heart Association grade III/IV) * History of alcohol abuse, defined as \>4 units of alcohol/day (32 g or 40 ml of 100% alcohol) * History of allergy for GLP-1 receptor agonists or DPP-4 inhibitors * Any disease that could interfere with study procedures (e.g. decreased mobility, mental incapacity) * Inability to give informed consent